Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PTN vs ATOS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATOS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 9–0 Matrix Metrics)

ATOS Overall Winner 6-Pillar Tally: PTN 2 – 4 ATOS Matrix Metrics: PTN 0 – 9 ATOS

As of Nov 16, 2026, Atossa Therapeutics, Inc. (ATOS) is the stronger overall head-to-head candidate over Palatin Technologies, Inc. (PTN) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PTN carries a Unified Composite Score of 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin), whereas ATOS carries 59.2/100 (HOLD) at $1.93 (7.0x Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: PTN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9); meanwhile ATOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PTN vs ATOS
PTN US Equity
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
TTM Revenue $13M
Forward P/E 42.9x
Beta / 30D Vol 0.87β · 106% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $5.72 · SMA50: $8.07
ATOS NASDAQ Head-to-Head Winner
Atossa Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.93
-1.53% 1D
Market Cap $19.6M
TTM Revenue N/A
Forward P/E 7.0x
Beta / 30D Vol 0.35β · 67% Vol
Unified Composite Score
59.2 / 100 HOLD
Tech 70.0 Fund 65.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 37
RSI-14: 36.6 · SMA20: $2.25 · SMA50: $2.32

6-Pillar Scorecard Institutional Category Breakdown (PTN 2 – 4 ATOS)

Columns: Metric · PTN · ATOS
1. Valuation Multiples ATOS
Forward P/E 42.9x 7.0x
Trailing P/E 42.9x 7.0x
PEG Ratio 1.62x N/M
EV / Revenue 0.1x N/M
2. Growth & Scale ATOS
Revenue Growth (YoY) -80.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $13M N/A
Market Cap $11.1M $19.6M
3. Profitability & Quality ATOS
Gross Margin 6.2% N/A
Operating Margin -65.7% 0.0%
Net Profit Margin -63.5% 0.0%
Return on Equity (ROE) -877.5% -96.9%
4. Balance Sheet & Cash Flow PTN
Cash Generation (TTM) -$15M -$35M
Cash Flow Margin -113.6% N/A
Net Cash / Leverage $9.9M Net Cash $2.18 Book/Sh · -96.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ATOS
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 141.8% (37th %ile)
Put/Call OI Skew N/A 0.24x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat PTN
OpEx & R&D Intensity 71.9% of Rev ($9.5M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PTN (0) vs ATOS (9)
Institutional Metric PTN ATOS Criterion Row Edge
Market Capitalization
Scale
$11.1M $19.6M Larger Scale Tie
Trailing P/E Ratio
Valuation
42.9x 7.0x Lower Multiple ATOS
Forward P/E Ratio
Valuation
42.9x 7.0x Lower Multiple ATOS
Revenue Growth (YoY)
Growth
-80.1% +0.0% Higher Growth ATOS
Operating Margin (TTM)
Profitability
-65.7% 0.0% Higher Margin ATOS
Net Profit Margin
Profitability
-63.5% 0.0% Higher Margin ATOS
Return on Equity (ROE)
Capital Efficiency
-877.5% -96.9% Higher ROE ATOS
52-Week Range Position
Momentum
6% ($5–$31) 20% ($1–$8) Stronger Trend ATOS
Beta / 30D Volatility
Risk Regime
0.87β · 106% Vol 0.35β · 67% Vol Lower Realized Risk ATOS
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 59.2 / 100 (HOLD) Higher Composite ATOS
Trailing 12M Revenue (USD)
Operating Scale
$13M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
6.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.62x PEG · 0.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M ($9.9M Net Cash) -$35M ($2.18 Book/Sh · -96.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTN +35.42 pp
PTN: +1.74% · ATOS: -33.68%
3M Horizon ATOS +16.24 pp
PTN: -41.72% · ATOS: -25.48%
6M Horizon ATOS +0.19 pp
PTN: -59.81% · ATOS: -59.62%
1Y Horizon ATOS +183.73 pp
PTN: -43.29% · ATOS: +140.44%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PTN Revenue ATOS Revenue PTN Op. Margin ATOS Op. Margin Margin Leader
FY2017 $70M N/A 38.6% N/A PTN
FY2018 $70M N/A 38.6% N/A PTN
FY2019 $60M N/A 59.3% N/A PTN
FY2020 $0M N/A -20007.6% N/A PTN
FY2022 $0M N/A -2491.6% N/A PTN
FY2023 $0M N/A -668.7% N/A PTN
FY2024 $0M N/A -501.0% N/A PTN
FY2026 $10M N/A -65.7% N/A PTN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PTN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PTN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ATOS BREAKDOWN
64d in phase · OBV NEUTRAL
Current IV 141.8%
IV Percentile 37th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ATOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PTN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $11.1M market capitalization and -65.7% operating margin.
OpEx & R&D Reinvestment 71.9% of Rev ($9.5M)
90D Engineering Disclosures 0 Published
ATOS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $19.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PTN vs ATOS Key Questions & Quantitative Answers

As of Nov 16, 2026, Atossa Therapeutics, Inc. (ATOS) is the stronger overall head-to-head candidate over Palatin Technologies, Inc. (PTN) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PTN carries a Unified Composite Score of 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin), whereas ATOS carries 59.2/100 (HOLD) at $1.93 (7.0x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: PTN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9); meanwhile ATOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ATOS leads the Growth & Scale pillar: PTN posts -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin), compared with ATOS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2026), PTN cumulative revenue shifted -85.7% while ATOS shifted N/A. In operating R&D and SG&A reinvestment, PTN deploys 71.9% of Rev ($9.5M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATOS.

ATOS screens cheaper on headline valuation multiples. PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin), whereas ATOS trades at 7.0x Forward P/E, 7.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PTN (-877.5% ROE) versus ATOS (-96.9% ROE) capital efficiency.

In options market volatility and institutional positioning, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk). By comparison, ATOS carries 141.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.35β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.